Venous Thromboembolism and Nonsmall Cell Lung Cancer A Pooled Analysis of National Cancer Institute of Canada Clinical Trials Group Trials

被引：70

作者：

Hicks, Lisa K. ^{[1
,2
]}

Cheung, Matthew C. ^{[2
,3
]}

Ding, Keyue ^{[4
]}

Hasan, Baktiar ^{[4
]}

Seymour, Lesley ^{[4
]}

Le Maitre, Aurelie ^{[4
]}

Leighl, Natasha B. ^{[2
,5
]}

Shepherd, Frances A. ^{[2
,5
]}

机构：

[1] St Michaels Hosp, Li Ka Shing Knowledge Inst, Keenan Res Ctr, Toronto, ON M5B 1X8, Canada

[2] Univ Toronto, Fac Med, Toronto, ON, Canada

[3] Sunnybrook Hlth Sci Ctr, Dept Med, Toronto, ON M4N 3M5, Canada

[4] Natl Canc Inst Canada, Clin Trials Grp, Kingston, ON, Canada

[5] Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M4X 1K9, Canada

来源：

CANCER | 2009年 / 115卷 / 23期

关键词：

lung neoplasms; complications; drug therapy; mortality; venous thromboembolism; epidemiology; etiology; adjuvant chemotherapy; antineoplastic combined chemotherapy protocols; CHRONIC KIDNEY-DISEASE; ORAL-CONTRACEPTIVE USE; DEEP-VEIN THROMBOSIS; MULTIPLE-MYELOMA; BREAST-CANCER; TISSUE FACTOR; RISK-FACTORS; CHEMOTHERAPY; ANGIOGENESIS; THALIDOMIDE;

D O I：

10.1002/cncr.24596

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BACKGROUND: Advanced nonsmall cell lung cancer (NSCLC) is associated with venous thromboembolism (VTE). However, to the authors' knowledge, the incidence of VTE in early NSCLC, predictors of VTE, and the prognostic significance of VTE in NSCLC have not been explored. METHODS: Individual patient data from 3 National Cancer Institute of Canada Clinical Trials Group trials were analyzed (n = 1987 patients). Clinical Trial BR.10 was a randomized study of postoperative vinorelbine and cisplatin versus observation in patients with stage IB/II NSCLC (grading determined according to the TNM staging system). Clinical Trial BR.18 was a randomized study of paclitaxel and carboplatin with or without the metalloproteinase inhibitor BMS-275291 in patients with advanced NSCLC. BR.21 was a randomized study of erlotinib versus placebo in patients with previously treated NSCLC. The relations between VTE, treatment, concomitant medications, and patient characteristics were explored in univariate and multivariate analyses. Survival analysis was completed using Cox regression. RESULTS: The incidence of VTE ranged from 0% in patients with early stage NSCLC on the observation arm of BR.10 to 7.9% in patients with advanced NSCLC who received chemotherapy (BR.18). Patients with early stage NSCLC who received chemotherapy (BR.10) and patients with previously treated NSCLC who received erlotinib or placebo (BR.21) had a VTE incidence of similar to 3%. Factors that were found to be predictive of VTE included previous VTE (BR.18; P = .001) and obesity (BR.10; P = .03). In patients with advanced NSCLC, VTE was associated with shorter survival (BR.18: hazard ratio [HR], 1,61; 95% confidence interval [95% CI], 1.26-2.07 [P = .0002]; BR.21: HR, 2.18; 95% Cl, 1.57-3.04 [P < .0001]). CONCLUSIONS: In patients with both early stage and advanced stage NSCLC, VTE occurred more frequently in patients who received chemotherapy (but not erlotinib or BMS-275291). In patients with advanced stage NSCLC, VTE was associated with obesity and a history of VTE. VTE was found to be prognostic in patients with advanced stage NSCLC. Cancer 2009;115:5516-25. (C) 2009 American Cancer Society.

引用

页码：5516 / 5525

页数：10

共 37 条

[11] Risk factors for deep vein thrombosis and pulmonary embolism -: A population-based case-control study [J].

Heit, JA ;

Silverstein, MD ;

Mohr, DN ;

Petterson, TM ;

O'Fallon, WM ;

Melton, LJ .

ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (06) :809-815

[12] Risk factors for venous thromboembolism [J].

Heit, JA .

CLINICS IN CHEST MEDICINE, 2003, 24 (01) :1-+

[13] Recent advances in the epidemiology, pathophysiology, and management of thrombosis in cancer patients [J].

Hicks, LK ;

Selby, R .

LABORATORY MEDICINE, 2004, 35 (08) :492-496

[14] Thromboembolism in hospitalized neutropenic cancer patients [J].

Khorana, AA ;

Francis, CW ;

Culakova, E ;

Fisher, RI ;

Kuderer, NM ;

Lyman, GH .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (03) :484-490

[15] Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study [J].

Khorana, AA ;

Francis, CW ;

Culakova, E ;

Lyman, GH .

CANCER, 2005, 104 (12) :2822-2829

[16] Development and validation of a predictive model for chemotherapy-associated thrombosis [J].

Khorana, Alok A. ;

Kuderer, Nicole M. ;

Culakova, Eva ;

Lyman, Gary H. ;

Francis, Charles W. .

BLOOD, 2008, 111 (10) :4902-4907

[17] The NCCN clinical practice guidelines on venous thromboembolic disease: Strategies for improving VTE prophylaxis in hospitalized cancer patients [J].

Khorana, Alok A. .

ONCOLOGIST, 2007, 12 (11) :1361-1370

[18]

KUDERER NM, 2008, J CLIN ONCOL, V26, pS507

[19] Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors [J].

Kuenen, BC ;

Rosen, L ;

Smit, EF ;

Parson, MRN ;

Levi, M ;

Ruijter, R ;

Huisman, H ;

Kedde, MA ;

Noordhuis, P ;

van der Vijgh, WJF ;

Peters, GJ ;

Cropp, GF ;

Scigalla, P ;

Hoekman, K ;

Pinedo, HM ;

Giaccone, G .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) :1657-1667

[20] Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18 [J].

Leighl, NB ;

Paz-Ares, L ;

Douillard, JY ;

Peschel, C ;

Arnold, A ;

Depierre, A ;

Santoro, A ;

Betticher, DC ;

Gatzemeier, U ;

Jassem, J ;

Crawford, J ;

Tu, DS ;

Bezjak, A ;

Humphrey, JS ;

Voi, M ;

Galbraith, S ;

Hann, K ;

Seymour, L ;

Shepherd, FA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) :2831-2839

← 1 2 3 4 →